DESTINY-Gastric01: Trastuzumab Deruxtecan in Previously Treated, HER2+ Advanced Gastric or GEJ Adenocarcinoma

May 29-31, 2020; Online at meetings.asco.org/am
In patients with advanced HER2+ gastric/GEJ cancer previously treated with trastuzumab, trastuzumab deruxtecan significantly improved response and OS vs standard chemotherapy.
Format: Microsoft PowerPoint (.ppt)
File Size: 242 KB
Released: June 1, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Daiichi Sankyo, Inc.

Related Content

Expert analysis module on key data from ESMO World GI 2022 in gastrointestinal cancers, from Clinical Care Options (CCO)

Joleen Hubbard, MD Rachna Shroff, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: October 4, 2022 Expired: October 3, 2023

Phase I/II ReFocus: RLY-4008 in patients with FGFR inhibitor-naive cholangiocarcinoma with FGFR2 alterations, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 22, 2022

From Clinical Care Options (CCO), download slides reviewing contemporary systemic therapy for HCC and BTC

James M. Cleary, MD, PhD Mark Yarchoan, MD Released: September 19, 2022

Primary results from phase III LEAP-002 study of lenvatinib with or without pembrolizumab as first-line treatment for patients with advanced hepatocellular carcinoma, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 19, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings